vs

Side-by-side financial comparison of AVADEL PHARMACEUTICALS PLC (AVDL) and Riley Exploration Permian, Inc. (REPX). Click either name above to swap in a different company.

Riley Exploration Permian, Inc. is the larger business by last-quarter revenue ($97.3M vs $77.5M, roughly 1.3× AVADEL PHARMACEUTICALS PLC). On growth, AVADEL PHARMACEUTICALS PLC posted the faster year-over-year revenue change (54.9% vs -5.3%). Over the past eight quarters, AVADEL PHARMACEUTICALS PLC's revenue compounded faster (99.6% CAGR vs -1.2%).

Avadel Pharmaceuticals, is an Irish specialty pharmaceutical company that focuses on sleep disorder medicines. Avadel markets products in the hospital and primary care spaces. The company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

AVDL vs REPX — Head-to-Head

Bigger by revenue
REPX
REPX
1.3× larger
REPX
$97.3M
$77.5M
AVDL
Growing faster (revenue YoY)
AVDL
AVDL
+60.1% gap
AVDL
54.9%
-5.3%
REPX
Faster 2-yr revenue CAGR
AVDL
AVDL
Annualised
AVDL
99.6%
-1.2%
REPX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
AVDL
AVDL
REPX
REPX
Revenue
$77.5M
$97.3M
Net Profit
$20.0K
Gross Margin
Operating Margin
2.5%
26.9%
Net Margin
0.0%
Revenue YoY
54.9%
-5.3%
Net Profit YoY
100.8%
EPS (diluted)
$0.00
$4.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVDL
AVDL
REPX
REPX
Q4 25
$97.3M
Q3 25
$77.5M
$106.9M
Q2 25
$68.1M
$85.4M
Q1 25
$52.5M
$102.5M
Q4 24
$50.4M
$102.7M
Q3 24
$50.0M
$102.3M
Q2 24
$41.5M
$105.4M
Q1 24
$27.2M
$99.7M
Net Profit
AVDL
AVDL
REPX
REPX
Q4 25
Q3 25
$20.0K
$16.3M
Q2 25
$9.7M
$30.5M
Q1 25
$-4.9M
$28.6M
Q4 24
$-5.0M
Q3 24
$-2.6M
$25.7M
Q2 24
$-13.8M
$33.5M
Q1 24
$-27.3M
$18.8M
Gross Margin
AVDL
AVDL
REPX
REPX
Q4 25
Q3 25
Q2 25
90.7%
Q1 25
89.4%
Q4 24
90.5%
Q3 24
87.7%
Q2 24
93.3%
Q1 24
94.4%
Operating Margin
AVDL
AVDL
REPX
REPX
Q4 25
26.9%
Q3 25
2.5%
27.0%
Q2 25
13.0%
33.7%
Q1 25
-5.7%
48.3%
Q4 24
-6.5%
31.2%
Q3 24
-0.7%
17.1%
Q2 24
-30.7%
50.9%
Q1 24
-95.8%
50.7%
Net Margin
AVDL
AVDL
REPX
REPX
Q4 25
Q3 25
0.0%
15.3%
Q2 25
14.2%
35.7%
Q1 25
-9.4%
27.9%
Q4 24
-10.0%
Q3 24
-5.2%
25.1%
Q2 24
-33.3%
31.8%
Q1 24
-100.6%
18.8%
EPS (diluted)
AVDL
AVDL
REPX
REPX
Q4 25
$4.02
Q3 25
$0.00
$0.77
Q2 25
$0.10
$1.44
Q1 25
$-0.05
$1.36
Q4 24
$-0.04
$0.52
Q3 24
$-0.03
$1.21
Q2 24
$-0.14
$1.59
Q1 24
$-0.30
$0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVDL
AVDL
REPX
REPX
Cash + ST InvestmentsLiquidity on hand
$91.6M
Total DebtLower is stronger
$247.9M
Stockholders' EquityBook value
$98.2M
$634.2M
Total Assets
$199.4M
$1.2B
Debt / EquityLower = less leverage
0.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVDL
AVDL
REPX
REPX
Q4 25
Q3 25
$91.6M
Q2 25
$81.5M
Q1 25
$66.5M
Q4 24
$73.8M
Q3 24
$65.8M
Q2 24
$71.4M
Q1 24
$88.8M
Total Debt
AVDL
AVDL
REPX
REPX
Q4 25
$247.9M
Q3 25
$367.0M
Q2 25
$275.2M
Q1 25
$249.3M
Q4 24
$269.5M
Q3 24
$288.6M
Q2 24
$322.7M
Q1 24
$341.8M
Stockholders' Equity
AVDL
AVDL
REPX
REPX
Q4 25
$634.2M
Q3 25
$98.2M
$566.5M
Q2 25
$90.7M
$556.9M
Q1 25
$74.1M
$532.4M
Q4 24
$73.8M
$510.6M
Q3 24
$74.7M
$507.4M
Q2 24
$70.3M
$489.0M
Q1 24
$78.4M
$434.6M
Total Assets
AVDL
AVDL
REPX
REPX
Q4 25
$1.2B
Q3 25
$199.4M
$1.2B
Q2 25
$187.2M
$1.0B
Q1 25
$167.9M
$994.9M
Q4 24
$164.2M
$993.5M
Q3 24
$158.3M
$997.9M
Q2 24
$157.5M
$1.0B
Q1 24
$167.9M
$956.4M
Debt / Equity
AVDL
AVDL
REPX
REPX
Q4 25
0.39×
Q3 25
0.65×
Q2 25
0.49×
Q1 25
0.47×
Q4 24
0.53×
Q3 24
0.57×
Q2 24
0.66×
Q1 24
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVDL
AVDL
REPX
REPX
Operating Cash FlowLast quarter
$22.2M
$64.9M
Free Cash FlowOCF − Capex
$22.2M
FCF MarginFCF / Revenue
28.7%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1110.25×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVDL
AVDL
REPX
REPX
Q4 25
$64.9M
Q3 25
$22.2M
$63.6M
Q2 25
$12.7M
$33.6M
Q1 25
$-8.2M
$50.4M
Q4 24
$7.9M
$66.4M
Q3 24
$-6.9M
$72.1M
Q2 24
$-18.2M
$51.6M
Q1 24
$-29.7M
$56.1M
Free Cash Flow
AVDL
AVDL
REPX
REPX
Q4 25
Q3 25
$22.2M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
AVDL
AVDL
REPX
REPX
Q4 25
Q3 25
28.7%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
AVDL
AVDL
REPX
REPX
Q4 25
Q3 25
0.0%
Q2 25
Q1 25
Q4 24
Q3 24
0.0%
Q2 24
Q1 24
Cash Conversion
AVDL
AVDL
REPX
REPX
Q4 25
Q3 25
1110.25×
3.90×
Q2 25
1.31×
1.10×
Q1 25
1.76×
Q4 24
Q3 24
2.81×
Q2 24
1.54×
Q1 24
2.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons